Lab on a Chip

Miniaturisation for chemistry, biology & bioengineering

Volume 8 | Number 3 | March 2008 | Pages 369–500

www.rsc.org/loc

Boston To Host 2nd Annual Event

Welcome to the second annual RNAi World Congress. The event is being held in Boston, home to many of the world's top institutions engaged in gene silencing research.

Keynote speakers include:

**Gregory Hannon** Professor, Cold Spring Harbor Laboratory

**Judy Lieberman** Senior Investigator, Harvard Medical School

**Craig Mello** Professor, University of Massachusetts

Be part of the event

We are currently accepting poster submissions. Deadlines and further details can be found online.

Corporate Sponsors

For sponsorship and exhibition opportunities contact Paul Raggett
tel: +44 (0) 1787 315117 email: paul.raggett@selectbiosciences.com

RNAiWorldCongress.com
Pre-binding dynamic range and sensitivity enhancement for immuno-sensors using nanofluidic preconcentrator†

Ying-Chih Wanga and Jongyoon Han* b

Received 7th November 2007, Accepted 21st December 2007
First published as an Advance Article on the web 14th January 2008
DOI: 10.1039/b717220f

Almost all immuno-biosensors are inherently limited by the quality of antibodies available for the target molecule, and obtaining a highly sensitive antibody for a given target molecule is a challenge. We describe a highly efficient and flexible way to enhance immunoassay detection sensitivity and binding kinetics using a nanofluidic based electrokinetic preconcentrator. The device is a microfluidic integration of charge-based biomolecule concentrator and a bead-based immunoassay. Because the preconcentrator can increase the local biomolecule concentration by many orders of magnitude, it gives the immuno-sensor better sensitivity and faster binding kinetics. With a 30 min pre-concentration, we were able to enhance the immunoassay sensitivity (with molecular background) by more than 500 fold from higher 50 pM to the sub 100 fM range. Moreover, by adjusting the preconcentration time, we can switch the detection range of the given bead-based assay (from 10–10000 ng ml−1 to 0.01–10000 ng ml−1) to have a broader dynamic range of detection. As the system can enhance both detection sensitivity and dynamic range, it can be used to address the most critical detection issues in the detection of common disease biomarkers.

Detecting low abundance biomolecules from either blood-stream or environmental samples has been a major challenge in proteomic studies and disease/pharmacokinetic biomarker monitoring. While immunoassays are the method of choice due to its high sensitivity, detection at ultra low concentration is still challenging. Recently, many significant advances have been reported for improving detection sensitivity of immunoassays. These include surface plasma resonance (SPR),1 cantilever based sensors,2 nanowire-based sensors,3 nanoparticle-based assays,4 optical microcavity sensors,5 and immuno-PCR techniques,6 with impressive detection sensitivities. Many of these novel immunoassays, however, still rely on the primary immunobinding between the low-concentration target and the antibody. The process is usually diffusion-limited,7,8 especially when the target concentration is significantly below the $K_d$ (dissociation constant, typically ranges from $10^{-5}$ to $10^{-12}$ M) of the antibody–antigen pair. Therefore, longer incubation (binding time) is required,9 and only a small fraction of targets are bound at binding equilibrium, leading to statistical noise in sensing. In addition, a good quality antibody (with low $K_d$) would be required to enable low-concentration sensing, which is not always feasible. Mirkin and coworkers4 improved binding kinetics by making much more antibodies (through the use of beads) available for the primary immuno-binding. Still, this technique would require chemical processing and relatively large sample volumes. The other critical issue of immunoassays is the dynamic range of detection, typically only ~$10^5$, while biomarker concentrations could vary over many orders of magnitude. When multiplexed detection of multiple biomarkers is desired, tracking various targets with large concentration differences posts formidable challenges.10,11

In this communication, we introduce a novel strategy using electrokinetic preconcentration for pre-binding concentration enhancement. Instead of chemically amplifying the signal after the primary immuno-reaction, we seek to increase the concentration of the target molecule before the reaction, using a unique molecular preconcentration device. In this way, one would be able to drive the kinetics of primary immuno-reaction toward the bound state, improving both the sensitivity and the speed of detection. This is demonstrated by integrating a standard bead-based immunoassay with a nanofluidic preconcentrator in a microfluidic device format. While pre-binding enhancement can be a powerful tool for immuno-sensing, it has only been realized in microchip electrophoretic immunoassay format with limited sensitivity improvement.12 Our recently developed nanofluidic preconcentrator,14 can precisely locate the collected molecule at a pre-determined spot with high preconcentration factors, therefore, is ideally suited for integration with bead/surface-based immunoassays. This strategy can be applied to most charged biomolecules by balancing the ion depletion force with counter flows (electrokinetic or pressure driven). Because it requires no physical confinement and complex buffer reagents, it has no interfacing issues with any other detectors, post amplification chemistries or multiplexing techniques.

The nanofluidic protein preconcentration device is shown in Fig. 1(a). Biomolecules are trapped by the depletion force coming from the nanofluidic concentration polarization effect. The details of the concentration polarization mechanism have been extensively studied in membrane science.15

When an electric field is applied across the nanochannel array (behaves as charge selective membrane due to electrical double layer overlapping), according to the classic theory of
concentration polarization, co-ions will be prohibited from entering the charge selective membrane. To maintain the charge neutrality in the vicinity of the membrane after selective positive ion transfer, the concentration of both positive and negative ions in the anodic side of the charge selective membrane will decrease. By balancing this depletion force with an external flow (pressure or electrokinetic driven), one can preconcentrate biomolecules as illustrated in Fig. 1(b) with high efficiency.

To integrate the preconcentrator with an immunoassay, bead-based antibody chemistry was chosen due to its flexibility and robustness. Streptavidin coated polystyrene beads (diameter 6–8 µm) were first labeled with biotinylated Green Fluorescent Protein (GFP) antibodies or R-phycoerythrin (R-PE) antibodies and then loaded into the device. To locate the assay adjacent to the preconcentrator, we used a two-step wet etching process to form a dam-like structure around the nanochannels with shallow region smaller than microbeads. The deep region was etched to a depth of 12 µm while the shallow region had only a 5.5 µm depth. The specificity of the bead assay was tested with R-PE on GFP antibodies labeled beads or vice versa, and no cross reactions between the two targets were observed. By coupling the immunoassay with the nanofluidic preconcentrator using this simple bead loading and preconcentration procedure, as shown in Fig. 2, one can locally increase the sample concentration and facilitate the binding kinetics and the sensitivity without changing the binding pair or detection system. The open geometry of this device makes it compatible to post amplification steps, various detectors and different antibody pairs for further enhancing the detection sensitivity.

With this device, bead-based immuno-sensing can be realized with or without preconcentration. Due to analyte depletion and/or the diffusive constraint, $K_d$ can be 10- to 100-fold smaller than a saturated situation at low target concentration environment. Therefore, as the antigen concentration decreases, the time required for binding equilibrium will increase dramatically. Such kinetic behavior is clearly shown in Fig. 3(a), where the equilibrium time of R-PE binding on primary antibodies (on beads) increases dramatically with decreasing target concentrations. As a result, when low concentration antigen diagnosis is needed, incubations from several hours to overnight are usually used. Such a long incubation is a common problem in immuno-biosensing once the analyte concentration goes below the scaling limit.

As described above, by coupling the nanofluidic preconcentrator with the bead-based assay, we can achieve a continuous on-site sample preconcentration on various charged biomolecules.
binding response is not affected by adding 10 fM range. In addition, the preconcentration and immunoassay can be done easily in the future. Meanwhile, any existing novel biosensing strategies that utilize post-binding amplification can also be coupled to further enhance the detection sensitivity and reliability with wider range of concentration variation.

Therefore, the presented strategy can be applied to different biomolecules with very little or no adaptation. Fig. 3(b) shows the dose response (binding curve) of this bead based immunoassay with the presence of background analytes (in this case, higher concentration of GFP). As we increase the reaction time from 30 min to 1 h, the response signal is marginally improved, without the significant changes in the lower detection limit maintained at around ~10 ng ml⁻¹ (~42 pM) level for the given monoclonal antibody–antigen (R-PE) pair. Nevertheless, by doing a 30 min on-site preconcentration, this system can lower the sensitivity limit by ~500 fold from the 50 pM to 100 fM range. In addition, the preconcentration and immunoassay can be done easily in the future. Meanwhile, any existing novel biosensing strategies that utilize post-binding amplification can also be coupled to further enhance the detection sensitivity and reliability with wider range of concentration variation.

In this communication, we have demonstrated that pre-binding preconcentration can solve many of the challenges in the early screening of common diseases biomarkers (dynamic range of detection, sensitivity, binding kinetics) without using ultra-sensitive biosensors, or high-quality antibodies. With a given antibody–antigen pair, the device can increase the dynamic range of detection, as well as the sensitivity (by at least 500 fold). This is of special importance when it comes to detecting low abundance markers after multiple sample preparation steps. Furthermore, through increasing the concentration of target antigen around the immunoassay site, the binding kinetics is significantly improved. This microfluidic device requires only a small amount of sample and reagent for detection, therefore, is ideal for miniaturized, point-of-care biosensing applications.

In additions, multiplexing for many different targets is highly feasible due to the possibility of massive parallelization of lab-on-a-chip systems and the use of commercialized bead-based sensors (flow cytometry assays like Bio-Plex from BioRad or xMAP from Luminex Corp.). Because of the simplicity of the presented method, the adaptation of this strategy to sandwich assays (using both primary and secondary antibodies) could be done easily in the future. Meanwhile, any existing novel biosensing strategies that utilize post-binding amplification can also be coupled to further enhance the detection sensitivity and reliability with wider range of concentration variation.

Acknowledgements

This work was supported by NIH grants including: CDP center (GM68762), NIBIB program (EB005743), and NCI program (CA119402).

Notes and references